-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
April 17, 2022/eMedClub News/--On March 31, 2022, the clinical trial application of the innovative drug ARB202 developed by ARBELE, a biotechnology company in Hong Kong Science Park, was approved by the Australian TGA.
About ARB202
About ARB202ARB202 is a First-in-Class bispecific antibody that targets gastrointestinal antigen CDH17 and T-cell CD3, developed based on Abella Pharma's unique and innovative CDH17 target
Preclinical results showed that ARB202 effectively enhanced the interaction between T cells and CDH17-expressing gastrointestinal tumor cell lines, resulting in the activation of T cells and the release of IL-2, which effectively produced tumor cell killing
At present, ARB202 has been officially approved by the Australian TGA to start a phase I clinical trial.
About ARBELE
About ARBELEFounded in 2016, Abella Biopharma is focused on inventing and developing breakthrough and innovative immunotherapies, providing first-in-class cancer drugs and high-quality diagnostic screening platforms for early disease intervention
▲Hong Kong Science & Technology Park Campus
▲Hong Kong Science & Technology Park Campus